Prestige Consumer Healthcare (PBH) Q1 2027 Earnings Call Transcript
Prestige Consumer Healthcare (PBH) reported Q1 fiscal 2027 sales of about $266 million, up 6.5%, with growth led by GI brands such as Dramamine and Fleet and skin care brands including Compound W. Adjusted EPS rose to $0.98 and adjusted free cash flow reached $83.7 million. PBH also completed acquisitions of the Breathe Right portfolio (closed June 12) and LaCorium (July 1).
How this was made
The 30-second read
Why it matters
Traders can update expectations for PBH’s near-term earnings power and cash generation, while also reassessing shipment timing and margin trajectory tied to Pillar5 and Clear Eyes capacity expansion.
Market read
Q1 financial metrics plus specific acquisition close dates and a Clear Eyes manufacturing recovery plan provide actionable updates for PBH positioning.
What to watch
Integration milestones are described as largely complete for Breathe Right, but the text does not quantify synergy timing or margin impact; investors may discount benefits until later quarters.
Background
The transcript summarizes Prestige Consumer Healthcare’s Q1 fiscal 2027 performance and discusses acquisition integration (Breathe Right and LaCorium) and the Pillar5 manufacturing investment tied to Clear Eyes recovery.
Ticker impact
Prestige Consumer Healthcare reports Q1 fiscal 2027 results with adjusted EPS of $0.98 and record adjusted free cash flow of $83.7M.
Moderately positive bias for PBH as investors weigh stronger cash generation and integration progress, though near-term Clear Eyes production variability is a potential offset.
The text includes specific financial metrics (sales growth, adjusted EPS, adjusted free cash flow) and new deal/integration timing (Breathe Right closed June 12, LaCorium closed July 1) plus a stated manufacturing ramp plan for Clear Eyes.
Market effects
Highlights continued consolidation and capacity investment in consumer health brands, potentially reinforcing M&A and manufacturing capex narratives in the category.
LaCorium contribution is largely Australia-based, which may modestly influence regional eye-care and dermal therapy demand expectations.
Breathe Right is sold in 20+ countries, so integration and marketing/innovation plans can affect global OTC wellness and sleep/sinus-adjacent brand sentiment.
Counterpoint
Despite record free cash flow, the company flags output variability in fiscal 2027 first half for Pillar5, which could pressure shipments and Clear Eyes momentum near term.
Key entities
- companyPrestige Consumer Healthcare
Subject of the earnings call transcript, reporting Q1 fiscal 2027 results, adjusted EPS, free cash flow, and acquisition/integration updates.
- acquisitionBreathe Right portfolio
Acquired portfolio closed June 12, expected to generate about $200M annual revenue and largely integrated within 60 days.
- acquisitionLaCorium Health
Australia-based dermal therapy business acquired, closed July 1, expected to contribute about $40M annualized revenue.
- capex_programPillar5 sterile ophthalmic manufacturing facility
Facility investment aimed at improving supply consistency and expanding Clear Eyes capacity, with expected first-half output variability in fiscal 2027.
